Blood Pressure Variability and Outcomes Across Antihypertensive Regimens.
HypertensionJun 25, 2026 (epub)
Yue Qiao, Zihan Sun, Eric L Harshfield et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial analyzed blood pressure variability (BPV) and cardiovascular outcomes in 5779 high-risk hypertensive patients using data from ACCORD-BP and SPRINT. CCB-based regimens showed significantly lower systolic BPV compared to RAS inhibitors and diuretics, with a β of -1.341 (P <0.001). However, no significant differences in major adverse cardiovascular events were found.
Key findings
- CCB-based regimens had significantly lower systolic BPV compared to RAS inhibitors (β=-1.341; P <0.001).
- CCB+diuretic regimens also showed lower BPV than RAS+diuretic regimens (β=-1.299; P <0.001).
- Only 3.7% of participants experienced major adverse cardiovascular events during the study.
Why it matters
Understanding the impact of different antihypertensive regimens on BPV can help clinicians optimize treatment strategies for high-risk patients, potentially improving cardiovascular outcomes.